List of Vistogard drug patents
Vistogard is owned by Wellstat Therap.
Vistogard contains Uridine Triacetate.
Vistogard has a total of 2 drug patents out of which 0 drug patents have expired.
Vistogard was authorised for market use on 11 December, 2015.
Vistogard is available in granule;oral dosage forms.
Vistogard can be used as emergency treatment of adult & pediatric patients following fluorouracil or capecitabine overdose,or who exhibit early-onset,severe or life-threatening cardiac or cns toxicity or unusually severe adverse reactions within 96 hours.
The generics of Vistogard are possible to be released after 17 August, 2027.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6258795 | WELLSTAT THERAP | Acylated uridine and cytidine and uses thereof |
Jul, 2023
(a month from now) | |
| US7776838 | WELLSTAT THERAP | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
Aug, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Dec 11, 2022 |
Drugs and Companies using URIDINE TRIACETATE ingredient
Market Authorisation Date: 11 December, 2015
Treatment: Emergency treatment of adult & pediatric patients following fluorouracil or capecitabine overdose,or who exhibit early-onset,severe or life-threatening cardiac or cns toxicity or unusually severe adve...
Dosage: GRANULE;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic